Literature DB >> 15700658

[Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children].

Ozgen Köseoğlu1, Alper Ergin, Nazli Gürkan Aydin, Gülşen Hasçelik.   

Abstract

Nasopharyngeal carriage of Moraxella catarrhalis is a risk factor for upper respiratory tract infections and otitis media. In this study, we aimed to characterize BRO beta-lactamases of M. catarrhalis strains isolated from 64 children without any symptoms of respiratory disease. Gram negative diplococci grown on selective media and which are catalase, oxidase, DNase, nitrate reduction positive, glucose, maltose, sucrose and lactose fermentation negative, were diagnosed as M. catarrhalis. Antibiotic susceptibility testing was performed by agar dilution method recommended by NCCLS. BRO beta-lactamases were differentiated by restriction enzyme analysis method. The resistance rate for ampicillin was 18.8% and all the isolates were found to be sensitive to amoxicillin-clavulanate, cefazolin, cefaclor, azithromycin and ciprofloxacin. Out of 64 M. catarrhalis isolates, 57 (89%) were found beta-lactamase positive with nitrocefin disk test (Remel, USA). The presence of BRO beta-lactamases in these 57 strains (89%) was also confirmed by restriction enzyme analysis, while 7 (11%) of them were found to be negative. Among the positive strains, 47 (73.4%) were typed as BRO-1, and 10 (15.6%) were typed as BRO-2. The characterization of BRO beta-lactamases of M. catarrhalis strains in carrier children is important since the high rate of carriage predisposes to respiratory tract infections. As a result, BRO beta-lactamase typing will guide the treatment regimen against the respiratory infections that can occur due to M. catarrhalis in carrier children.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15700658

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  1 in total

1.  Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004).

Authors:  Lalitagauri M Deshpande; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.